ResultsIQ

ResultsIQ › Latest results › Syngene International Limited

Syngene International Limited strategy deck summary

NSE: SYNGENE · BSE: 539268

Strategy deck of 9 Sep 2025, summarised by AI from the filing.

Unit-3 facility became operational in Q1 FY26; guidance maintained for asset turnover of 1x in less than 5 years and PAT contribution from FY27.

Key takeaways

  1. Unit-3 operational Part of Unit-3 facility became operational in Q1 FY26; delivered a GMP clinical batch of drug substance for a US based client.
  2. Guidance Asset turnover of 1x in less than 5 years; EBITDA margins in line with Company average from FY29; PAT contribution from FY27.
  3. Change Facility was part capitalized in Q1 FY26 and received local regulatory approvals in May 2025.
  4. Driver Focus on building pipeline across human and animal health, integrated clinical manufacturing projects, and cost efficiency through process innovation.

Original filing on BSE

Syngene International Limited Q1 FY27 results

As filed: Revenue ₹736 cr (−16% year on year), EBITDA ₹90.8 cr (−56% year on year), PAT −₹9.0 cr (−106% year on year), EBITDA margin 12.3% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,037 cr (+2% year on year), EBITDA ₹303 cr (−12% year on year), PAT ₹148 cr (−19% year on year), EBITDA margin 29.3% (−452 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 452 bps year on year. Share price after the results: +2.3% in 30 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹917 cr (−3% year on year), EBITDA ₹209 cr (−26% year on year), PAT ₹15.0 cr (−45% year on year), EBITDA margin 22.8% (−727 bps). Score 8 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 727 bps year on year. Other income 54% of PBT. Tax rate 47%. Share price after the results: −24.0% in 29 days (Nifty 500: +1.7%).
  • Q2 FY26: Revenue ₹911 cr (+2% year on year), EBITDA ₹200 cr (−18% year on year), PAT ₹67.0 cr (−37% year on year), EBITDA margin 22.0% (−543 bps). Score 23 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 543 bps year on year. Profit fell 23% from last quarter. Share price after the results: −1.0% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹875 cr (+11% year on year), EBITDA ₹206 cr (+21% year on year), PAT ₹87.0 cr (+14% year on year), EBITDA margin 23.5% (+202 bps). Score 71 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 202 bps year on year. Tax rate 15%. Revenue fell 14% from last quarter. Share price after the results: −1.3% in 30 days (Nifty 500: −1.4%).
  • Q4 FY25: Revenue ₹1,018 cr (+11% year on year), EBITDA ₹344 cr (+9% year on year), PAT ₹183 cr (−3% year on year), EBITDA margin 33.8% (−78 bps). Score 61 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin fell 78 bps year on year. Share price after the results: −14.9% in 30 days (Nifty 500: +2.4%).
  • Q3 FY25: Revenue ₹944 cr (+11% year on year), EBITDA ₹284 cr (+22% year on year), PAT ₹131 cr (+17% year on year), EBITDA margin 30.1% (+292 bps). Score 84 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 292 bps year on year.
  • Q2 FY25: Revenue ₹891 cr (−2% year on year), EBITDA ₹244 cr (−4% year on year), PAT ₹106 cr (−9% year on year), EBITDA margin 27.4% (−53 bps). Score 26 of 100, Below trend. EBITDA margin fell 53 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Syngene International Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.